Información del autor
Documentos disponibles escritos por este autor (4)
Añadir el resultado a su cesta Hacer una sugerencia Refinar búsqueda
texto impreso
The prevalence of non-communicable diseases is increasing worldwide, which coincides with the persistence of infectious diseases including tuberculosis. These can synergistically affect individual and population health. Three non-communicable di[...]texto impreso
Sheen, P. ; Monsalve, A. ; Campos, J. ; Huerta, R. ; Antiparra, R. ; Arteaga, H. ; Duran, P. ; Bueno, C. ; Kirwan, D.E. ; Gilman, R.H. ; Zimic, M. | American Society for Microbiology | 2020-12-14T16:10:13ZMycobacterium tuberculosis nicotinamidase-pyrazinamidase (PZAse) is a metalloenzyme that catalyzes conversion of nicotinamide-pyrazinamide to nicotinic acid-pyrazinoic acid. This study investigated whether a metallochaperone is required for opti[...]texto impreso
Alcántara, R. ; Fuentes, P. ; Antiparra, R. ; Santos, M. ; Gilman, R.H. ; Kirwan, D.E. ; Zimic, M. ; Sheen, P. | American Society for Microbiology | 2019-12-06T21:02:57ZAlthough pyrazinamide (PZA) is a key component of first- and second-line tuberculosis treatment regimens, there is no gold standard to determine PZA resistance. Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% of exten[...]texto impreso
Vallejos-Sánchez, K. ; Lopez, J.M. ; Antiparra, R. ; Toscano, E. ; Saavedra, H. ; Kirwan, D.E. ; Amzel, L.M. ; Gilman, R.H. ; Maruenda, H. ; Sheen, P. ; Zimic, M. | Nature Research | 2020-12-14T16:10:22ZPyrazinamide (PZA) is an antibiotic used in first- and second-line tuberculosis treatment regimens. Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensively drug-resistant tuberculosis strains are also PZA resistant. Des[...]
